Skip to main content
OpenTrials
Completed

NCT Number: NCT01719913

The Effect of Gluten on Gut Microbiome and Metabolic Health.

Objective: To identify how specific changes of the gluten content in the diet affect the host-gut microbiome interactions with implications for metabolic health.

Design: A randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included.

Intervention: low vs high gluten intake.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Novo Nordisk Foundation of Basic Metabolic Health, Section for Metabolic Genetics

Copenhagen, 2100, Denmark

About this study

The study is designed as a randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included. Participants consume, in randomized order, a gluten-poor diet (<5 g/d) in the active treatment period and a gluten-rich diet (>25 g/d) during the control period.

Measurements: Altered quantitative metagenomics at bacterial gene- and species levels is the primary outcome of this study. Secondary outcomes include metabolic and inflammatory markers, circulating appetite hormone levels,serum metabolomics, gastrointestinal transit time and intestinal permeability. Furthermore, selected control measures are included; 4-day food records and a study intervention dietary records.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

, compulsory:

  • Body mass index (BMI): 25 - 35 kg/m2 OR
  • Abdominal obesity: waist circumference: men: ≥ 94cm; women: ≥ 80cm
  • No medically prescribed diet
  • Weight stable
  • Intense sporting activities less than 10 h/week
  • Alcohol consumption less than 14 units/week (female) and 21 units/week (male)
  • Signed informed consent

Inclusion criteria

, minimum one of the following:

  • Fasting plasma glucose from 6.1 mmol/l to 6.9 mmol/l
  • Reduced high density lipoprotein (HDL) cholesterol; HDL ≤ 1.03 mmol/L for men and ≤ 1.29 mmol/L for women
  • Increased triglyceride (TG) > 1.3 mmol/L
  • Systolic blood pressure > 130 mmHg

Exclusion criteria

  • Pharmacological treatment; diabetes and blood lipid regulation
  • Lactating (or lactating, 6 weeks ago), pregnant (or pregnant, 3 months ago) or wish to become pregnant during the study
  • Participation in another biomedical trial 1 month prior to study start
  • Diagnosed with any form of diabetes, celiac disease or chronic pancreatitis
  • Reported chronic gastrointestinal disorders
  • Antibiotic treatment for 3 month prior to study start
  • Blood hemoglobin < 7.0 mmol/l
  • Blood donation within 1 month prior to study start

Treatment and study plan

High gluten

Other

Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)

Low gluten

Other

Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)

Primary outcomes

  1. Altered quantitative metagenomics at bacterial gene- and species levels.

    Time frame: Up to 3 years.

    Feces samples are collected according to standard operation procedures for subsequent standardized microbial DNA extraction. Microbial DNA will be subjected to sequencing, microbial gene analyses, taxonomy analyses including enterotypes known species and unknown meta-species and functional annotation.

Secondary outcomes

  1. Mean intestinal transit time

    Time frame: Up to 2 years.

    Participants are instructed in swallowing capsules containing different small non-invasive and non-absorbable plastic pellets for 6 consecutive days. On the seventh day they are having an X-ray of the abdomen taken.

  2. Gastrointestinal permeability.

    Time frame: Up to 2 years.

    Lactulose/mannitol ratio in urine after four hours collection following oral intake of lactulose and mannitol.

  3. Colonic fermentation

    Time frame: Up to 2 years.

    Breath hydrogen after intake of standardized breakfast (30,60,90,120,180 minutes)

  4. Blood pressure and pulse.

    Time frame: Up to 1 year.

    Systolic and diastolic blood pressure and heart beat rate are measured after 10 min of rest according to current standard operational procedure with an automatic blood pressure meter. Participants are instructed not to talk during the measurements.

  5. Saliva microbial flora

    Time frame: Up to 2 years.

    Saliva is collected after the participants have taken a small piece of paraffin in their mouth and have chewed until the paraffin has turned into one coherent mass (approximately one minute). Participants are swallowing the produced saliva for that minute. After this, and for the next 3 minutes, saliva is collected in a cup and handed over to the study personnel. Saliva is stored at minus 80 degrees for later studies of saliva microbial flora and saliva biochemistry.

  6. Nasal fluid

    Time frame: Up to 3 years.

    Nasal fluid is collected by a non-invasive methodology for in vivo measurement of an array of immunological signalling molecules in the nasal airway lining. The method is based on a standardized collection of mucosal airway fluid from both nostrils onto small sheets of filter papers with efficient absorption properties. The technique is highly reproducible, and used for measuring immunological mediators representing the immediate response ability of the mucosal immune system.

  7. Appetite hormones

    Time frame: Up to 3 years.

    Glucagon like peptide 1 and 2, Gastric inhibitory polypeptide, peptide YY and Ghrelin.

  8. Celiac disease markers

    Time frame: Up to 1 year.

    Levels of gliadin and Immunoglobulin A and G transglutaminase.

  9. Blood lipid profile

    Time frame: Up to 2 years.

    Low density Lipoproteins, High density lipoproteins, Total Cholesterol, Very low density lipoproteins and Free fatty acids.

  10. Bioimpedance

    Time frame: Up to 1 year.

    Body composition (lean body mass and fat mass) is measured by bio-electrical impedance using multi frequency Quadscan.

  11. Breath hydrogen.

    Time frame: Up to 2 years.

    Breath hydrogen measurements are done before the intake of the standardized breakfast (at 30, 60, 90, 120, 180 minutes), as an indicator of colonic fermentation.

  12. Insulin

    Time frame: Up to 2 years.

    Fasting insulin and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.

  13. Glucose

    Time frame: Up to 2 years.

    Fasting glucose and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.

  14. C-peptide

    Time frame: Up to 2 years.

    Fasting.

  15. Inflammatory makers

    Time frame: Up to 3 years.

    High sensitive C-reactive protein, Interleukin 1, 6 and 10, Lipopolysaccharide- binding protein, Tumor necrosis factor - alfa.

  16. Anthropometric characteristics.

    Time frame: Up to 1 year.

    Weight, height, sagittal height and waist circumference.

Other outcomes

  1. 4 days precoded food diary.

    Time frame: Up to 2 years.

    Validated method for dietary registration, based on 2 week and 2 weekend days.

  2. Gastrointestinal symptoms.

    Time frame: Up to 2 years.

    Changes from baseline to after intervention in individual gastrointestinal symptoms by validated VAS-questionary.

Sponsors and collaborators

Lead sponsor

University of Copenhagen

Other

Collaborators

  • Technical University of Denmark

Registry information

Official study title

Gut, Grain and Greens (3G): The Effect of Gluten on Gut Microbiome and Metabolic Health.

Acronym: 3G

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Nov 1, 2012
Registry last updated
Dec 5, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.